Literature DB >> 34331683

Targeting Nuclear Factor-Kappa B Signaling Pathway by Curcumin: Implications for the Treatment of Multiple Sclerosis.

Meysam Gachpazan1,2, Sadra Habbibirad1, Hoda Kashani1, Tannaz Jamialahmadi3,4, Hamid Reza Rahimi5, Amirhossein Sahebkar6,7,8.   

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, which involves an auto-immune mechanism that leads to perivascular demyelination. The role of nuclear factor-kappa B (NF-κB) signaling pathway in the pathogenesis of MS has been suggested by genome-wide association studies. Therefore, strategies targeting this pathway could be potentially beneficial. Curcumin is the active component of turmeric and a phenolic phytochemical. This phytochemical has anti-inflammatory properties and has been shown by multiple studies to downregulate NF-κB and its downstream gene targets including cyclooxygenase-2, tumor necrosis factor-α, interleukin-1, and interleukin-6. This review discusses the modulatory effects of curcumin on the NF-κB signaling pathway and its downstream effectors, and the therapeutic implications of this modulation on MS.
© 2021. The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Curcumin; MS; Multiple sclerosis; NF-kappa B; Nuclear factor-kappa B

Mesh:

Substances:

Year:  2021        PMID: 34331683     DOI: 10.1007/978-3-030-56153-6_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  80 in total

Review 1.  A molecular trio in relapse and remission in multiple sclerosis.

Authors:  Lawrence Steinman
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

Review 2.  Immunology of multiple sclerosis.

Authors:  Mireia Sospedra; Roland Martin
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 3.  Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges.

Authors:  C Trebst; R M Ransohoff
Journal:  Arch Neurol       Date:  2001-12

Review 4.  Effector T Cells in Multiple Sclerosis.

Authors:  Belinda J Kaskow; Clare Baecher-Allan
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 5.  Multiple Sclerosis Pathology.

Authors:  Hans Lassmann
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

6.  Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions.

Authors:  J E Simpson; J Newcombe; M L Cuzner; M N Woodroofe
Journal:  Neuropathol Appl Neurobiol       Date:  2000-04       Impact factor: 8.090

7.  Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system.

Authors:  Torben L Sørensen; Corinna Trebst; Pia Kivisäkk; Karen L Klaege; Amit Majmudar; Rivka Ravid; Hans Lassmann; David B Olsen; Robert M Strieter; Richard M Ransohoff; Finn Sellebjerg
Journal:  J Neuroimmunol       Date:  2002-06       Impact factor: 3.478

8.  Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis.

Authors:  Adam P Kohm; Pamela A Carpentier; Holly A Anger; Stephen D Miller
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

9.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.

Authors:  John S Tzartos; Manuel A Friese; Matthew J Craner; Jackie Palace; Jia Newcombe; Margaret M Esiri; Lars Fugger
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

10.  Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis.

Authors:  Caterina Veroni; Barbara Serafini; Barbara Rosicarelli; Corrado Fagnani; Francesca Aloisi
Journal:  J Neuroinflammation       Date:  2018-01-16       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.